New drug hope for rare inflammatory VEXAS syndrome

NCT ID NCT07098936

Recruiting now Disease control Sponsor: Groupe Francophone des Myelodysplasies Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 2 times

Summary

This phase 2 trial tests the drug momelotinib in 57 people with VEXAS syndrome, a rare inflammatory condition that may also involve a bone marrow disorder called MDS. Participants receive momelotinib daily, and doctors check if symptoms improve and if steroid doses can be lowered. The study first finds the safest dose, then measures how well the drug controls the disease over 24 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: momelotinib
What this could lead to: If it works, this could offer a new treatment option to control VEXAS syndrome symptoms and reduce reliance on steroids.
What could go wrong: This is an early phase 2 trial with only 57 participants, so results may not apply to everyone. The drug may cause side effects or fail to improve symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELO DYSPLASTIC SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myelodysplastic syndrome Myelodysplastic Syndromes VEXAS syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELO DYSPLASTIC SYNDROME VEXAS SYNDOME

Contacts and locations

Locations

CH Lyon sud - Service d'Hématologie Clinique
RECRUITING

Pierre-Bénite, 69495, France
CHU Estaing - Service d'Hématologie Clinique
NOT_YET_RECRUITING

Clermont-Ferrand, 63000, France
CHU Nantes - Hôtel Dieu - Service d'Hématologie Clinique
NOT_YET_RECRUITING

Nantes, 44093, France
CHU d'Angers - Service des Maladies du sang
RECRUITING

Angers, 49933, France
CHU de Haut-Lévèque - Centre F. Magendie - Service des Maladies du sang
NOT_YET_RECRUITING

Pessac, 33604, France
CHU de Tours - Hôpital Bretonneau - Service de Médecine Interne
NOT_YET_RECRUITING

Tours, 37044, France
Hôpital Claude Huriez - Service de Médecine Interne
NOT_YET_RECRUITING

Lille, 59037, France
Hôpital Pontchaillou Service d'hématologie clinique et service de médecine interne
NOT_YET_RECRUITING

Rennes, 35033, France
Hôpital Saint Louis - Service hématologie séniors
NOT_YET_RECRUITING

Paris, 75010, France
Hôpital Saint-Antoine - Service de Médecine Interne
NOT_YET_RECRUITING

Paris, 75012, France
IUCT Oncopole Département d'hématologie / Unité de médecine interne
NOT_YET_RECRUITING

Toulouse, 31059, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.